(PubMed) Lepage G, Levy E, Ronco N, Smith L, Galeano N, Roy CC
A product that promises to "fix GLP-1 side effects" is making a claim beyond what the evidence supports
F.EssopM
They underscore not only the clinical impact of this drug class but also the urgent need to comprehensively review the evolving evidence base, clarify mechanistic insights, and explore future directions in both metabolic and non-metabolic disease contexts
With BPC 157 additional therapy, there are no characteristic corticosteroid adverse effects in the corticosteroid animals (Sikiric et al., 2003)
However, these medications also face several challenges, including low stability in the body, short half-lives, poor membrane permeability, complex manufacturing processes, and high costs